throbber
(12) United States Patent
`Knudsen et al.
`
`USOO6268343B1
`(10) Patent No.:
`US 6,268,343 B1
`(45) Date of Patent:
`Jul. 31, 2001
`
`(54) DERIVATIVES OF GLP-1ANALOGS
`(75) Inventors: Liselotte Bjerre Knudsen, Valby; Per
`Olaf Huusfeldt, Kobenhavn K; Per
`Franklin Nielsen, Vaerlose; Niels C.
`Kaarsholm, Vanløse; Helle Birk Olsen,
`Allerød; Søren Erik Bjørn, Lyngby;
`Freddy Zimmerdahl Pedersen; Kjeld
`Madsen, both of Vaerløse, all of (DK)
`
`(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)
`Subject to any disclaimer, the term of this
`(*) Notice:
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.: 09/258,750
`(22) Filed:
`Feb. 26, 1999
`Related U.S. Application Data
`(63) Continuation-in-part of application No. 09/038,432, filed on
`Mar. 11, 1998, now abandoned, which is a continuation-in
`part of application No. 08/918,810, filed on Aug. 26, 1997,
`now abandoned, and a continuation-in-part of application
`No. PCT/DK97/00340, filed on Aug. 22, 1997
`(60) Provisional application No. 60/035,904, filed on Jan. 24,
`1997, provisional application No. 60/036,226, filed on Jan.
`25, 1997, provisional application No. 60/036,255, filed on
`Jan. 24, 1997, provisional application No. 60/082,478, filed
`on Apr. 21, 1998, provisional application No. 60/082,480,
`filed on Apr. 21, 1998, provisional application No. 60/082,
`802, filed on Apr. 23, 1998, and provisional application No.
`60/084,357, filed on May 5, 1998.
`Foreign Application Priority Data
`(30)
`Aug. 30, 1996 (DK) ................................................... O931/96
`Nov. 8, 1996 (DK) ................................................... 1259/96
`Dec. 20, 1996 (DK) ................................................... 1470/96
`Feb. 27, 1998 (DK).
`... 0263/98
`Feb. 27, 1998 (DK).
`... O264/98
`Feb. 27, 1998 (DK).
`... 0268/98
`Feb. 27, 1998 (DK)
`O272/98
`O274/98
`Feb. 27, 1998 (DK)
`... 0508/98
`Apr. 8, 1998 (DK) ...
`Apr. 8, 1998 (DK) ................................................... 0509/98
`
`
`
`(51) Int. Cl." .......................... A61K 39/16; A61K 38/26;
`C07K 14/00; CO7K 14/605
`(52) U.S. Cl. ............................................... 514/12; 530/324
`(58) Field of Search ................................ 530/324; 514/12
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`6/1992 Habener ................................. 514/12
`4/1996 Chen et al. ......
`... 514/12
`8/1996 Buckley et al. .
`... 514/12
`3/1997 Habener ................................. 514/12
`
`5,120,712
`5,512,549
`5,545,618
`5,614,492
`
`O 708 179
`WO 90/11296
`WO 91/11457
`WO95/07931
`WO95/31214
`WO 96/29342
`WO 96/29344
`WO 87/06941
`WO 98/08531
`WO 98/O8871
`WO 98/O8873
`WO 98/19698
`
`FOREIGN PATENT DOCUMENTS
`4/1996 (EP).
`10/1990 (WO).
`8/1991 (WO).
`3/1995 (WO).
`11/1995 (WO).
`9/1996 (WO).
`9/1996 (WO).
`11/1997 (WO).
`3/1998 (WO).
`3/1998 (WO).
`3/1998 (WO).
`5/1998 (WO).
`OTHER PUBLICATIONS
`Kim et al., (1994) J. of Pharma, Sciences 83(8); 1175–1180.
`Clodfelter et al., (1998) Pharmaceutical Res. 15(2):254-262.
`Primary Examiner Michael Borin
`(74) Attorney, Agent, or Firm-Steve T. Zelson, Esq.; Elias
`J. Lambiris, Esq.
`ABSTRACT
`(57)
`The present invention relates to GLP-1 derivatives having a
`lipophilic Substituent, pharmaceutical compositions com
`prising Same, and methods of making an using Same. The
`GLP-1 derivatives of the present invention have a protracted
`profile of action.
`
`40 Claims, 1 Drawing Sheet
`
`MPI EXHIBIT 1034 PAGE 1
`
`DR. REDDY’S LABORATORIES, INC.
`IPR2024-00009
`Ex. 1034, p. 1 of 137
`
`

`

`U.S. Patent
`
`Jul. 31, 2001
`
`US 6,268,343 B1
`
`Fig. 1
`
`
`
`O.1
`
`1
`
`10
`peptide (uM)
`
`100
`
`1OOO
`
`MPI EXHIBIT 1034 PAGE 2
`
`DR. REDDY’S LABORATORIES, INC.
`IPR2024-00009
`Ex. 1034, p. 2 of 137
`
`

`

`1
`DERVATIVES OF GLP-1. ANALOGS
`
`CROSS-REFERENCE TO RELATED
`APPLICATIONS
`This application is a continuation-in-part of Ser. No.
`09/038,432 filed Mar. 11, 1998, now abandoned which is a
`continuation-in-part of Ser. No. 08/918,810 filed Aug. 26,
`1997 now abandoned and of PCT application serial no.
`PCT/DK97/00340 filed Aug. 22, 1997, and claims priority
`of U.S. provisional application Ser. Nos. 60/035,904,
`60/036,226, 60/036,255, 60/082,478, 60/082,480, 60/082,
`802, and 60/084,357 filed Jan. 24, 1997, Jan. 25, 1997, Jan.
`24, 1997, Apr. 21, 1998, Apr. 21, 1998, Apr. 23, 1998, and
`May 5, 1998, respectively, and of Danish application serial
`nos. 0931/96, 1259/96, 1470/96, 0263/98, 0264/98, 0268/
`98,0272/98, 0274/98, 0508/98, and 0509/98 filed Aug. 30,
`1996, Nov. 8, 1996, Dec. 20, 1996, Feb. 27, 1998, Feb. 27,
`1998, Feb. 27, 1998, Feb. 27, 1998, Feb. 27, 1998, Apr. 8,
`1998, and Apr. 8, 1998, respectively, the contents of each of
`which is fully incorporated herein by reference.
`FIELD OF THE INVENTION
`The present invention relates to novel derivatives of
`human glucagon-like peptide-1 (GLP-1) and fragments and/
`or analogues thereof which have a protracted profile of
`action and to methods of making and using them.
`BACKGROUND OF THE INVENTION
`Peptides are widely used in medical practice, and Since
`they can be produced by recombinant DNA technology it
`can be expected that their importance will increase also in
`the years to come. When native peptides or analogues
`thereof are used in therapy it is generally found that they
`have a high clearance. A high clearance of a therapeutic
`agent is inconvenient in cases where it is desired to maintain
`a high blood level thereof over a prolonged period of time
`Since repeated administrations will then be necessary.
`Examples of peptides which have a high clearance are:
`ACTH, corticotropin-releasing factor, angiotensin,
`calcitonin, insulin, glucagon, glucagon-like peptide-1,
`glucagon-like peptide-2, insulin-like growth factor-1,
`insulin-like growth factor-2, gastric inhibitory peptide,
`growth hormone-releasing factor, pituitary adenylate
`cyclase activating peptide, Secretin, enterogastrin,
`Somatostain, Somatotropin, Somatomedin, parathyroid
`hormone, thrombopoietin, erythropoietin, hypothalamic
`releasing factors, prolactin, thyroid Stimulating hormones,
`endorphins, enkephalins, vasopressin, oxytocin, opiods and
`analogues thereof, Superoxide dismutase, interferon,
`asparaginase, arginase, arginine deaminase, adenosine
`deaminase and ribonuclease. In Some cases it is possible to
`influence the release profile of peptides by applying Suitable
`pharmaceutical compositions, but this approach has various
`Shortcomings and is not generally applicable.
`The hormones regulating insulin Secretion belong to the
`So-called enteroinsular axis, designating a group of
`hormones, released from the gastrointestinal mucosa in
`response to the presence and absorption of nutrients in the
`gut, which promote an early and potentiated release of
`insulin. The enhancing effect on insulin Secretion, the
`So-called incretin effect, is probably essential for a normal
`glucose tolerance. Many of the gastrointestinal hormones,
`including gastrin and Secretin (choleystokinin is not insuli
`notropic in man), are insulinotropic, but the only physiologi
`cally important ones, those that are responsible for the
`incretin effect, are the glucose-dependent insulinotropic
`
`5
`
`15
`
`25
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`US 6,268,343 B1
`
`2
`polypeptide, GIP, and glucagon-like peptide-1 (GLP-1).
`Because of its insulinotropic effect, GIP, isolated in 1973 (1)
`immediately attracted considerable interest among diabe
`tologist. However, numerous investigations carried out dur
`ing the following years clearly indicated that a defective
`secretion of GIP was not involved in the pathogenesis of
`insulin dependent diabetes mellitus (IDDM) or non insulin
`dependent diabetes mellitus (NIDDM)(2). Furthermore, as
`an insulinotropic hormone, GIP was found to be almost
`ineffective in NIDDM (2). The other incretin hormone,
`GLP-1 is the most potent insulinotropic Substance known
`(3). Unlike GIP, it is surprisingly effective in stimulating
`insulin secretion in NIDDM patients. In addition, and in
`contrast to the other insulinotropic hormones (perhaps with
`the exception of Secretin) it also potently inhibits glucagon
`Secretion. Because of these actions it has pronounced blood
`glucose lowering effects particularly in patients with
`NIDDM.
`GLP-1, a product of the proglucagon (4), is one of the
`youngest members of the secretin-VIP family of peptides,
`but is already established as an important gut hormone with
`regulatory function in glucose metabolism and gastrointes
`tinal Secretion and metabolism (5). The glucagon gene is
`processed differently in the pancreas and in the intestine. In
`the pancreas (9), the processing leads to the formation and
`parallel Secretion of 1) glucagon itself, occupying positions
`33-61 of proglucagon (PG); 2) an N-terminal peptide of 30
`amino acids (PG (1-30)) often called glicentin-related pan
`creatic peptide, GRPP (10,11); 3) a hexapeptide correspond
`ing to PG (64–69); and, finally, the so-called major proglu
`cagon fragment (PG (72–158)), in which the two glucagon
`like sequences are buried (9). Glucagon seems to be the only
`biologically active product. In contrast, in the intestinal
`mucosa, it is glucagon that is buried in a larger molecule,
`while the two glucagon-like peptides are formed Separately
`(8). The following products are formed and secreted in
`parallel: 1) glicentin, corresponding to PG (1-69), with the
`glucagon Sequence occupying residues Nos. 33–61 (12); 2)
`GLP-1 (7-36)amide (PG(78-107)amide (13), not as origi
`nally believed PG (72-107)amide or 108, which is inactive).
`Small amounts of C-terminally glycine-extended but equally
`bioactive GLP-1(7–37), (PG (78–108)) are also formed (14);
`3) intervening peptide-2(PG (111-112)amide) (15); and 4)
`GLP-2 (PG(126–158))(15, 16). A fraction of glicentin is
`claved further into GRPP (PG (1–30)) and oxyntomodulin
`(PG (33–69)) (17, 18). Of these peptides, GLP-1, has the
`most conspicuous biological activities.
`Being Secreted in parallel with glicentin/enteroglucagon,
`it follows that the many Studies of enteroglucagon Secretion
`(6, 7) to some extent also apply to GLP-1 secretion, but
`GLP-1 is metabolised more quickly with a plasma half-life
`in humans of 2 min (19). Carbohydrate or fat-rich meals
`Stimulate (20), presumably as a result of direct interaction of
`yet unabsorbed nutrients with the microVilli of the open-type
`L-cells of the gut mucosa. Endocrine or neural mechanisms
`promoting GLP-1. Secretion may exist but have not yet been
`demonstrated in humans.
`The incretin function of GLP-1 (29-31) has been clearly
`illustrated in experiments with the GLP-1 receptor
`antagonist, exendin 9-39, which dramatically reduces the
`incretin effect elicited by oral glucose in rats (21, 22). The
`hormone interacts directly with the f-cells via the GLP-1
`receptor (23) which belongs to the glucagon/VIP/calcitonin
`family of G-protein-coupled- 7-transmembrane Spanning
`
`MPI EXHIBIT 1034 PAGE 3
`
`DR. REDDY’S LABORATORIES, INC.
`IPR2024-00009
`Ex. 1034, p. 3 of 137
`
`

`

`US 6,268,343 B1
`
`3
`receptors. The importance of the GLP-1 receptor in regu
`lating insulin Secretion was illustrated in recent experiments
`in which a targeted disruption of the GLP-1 receptor gene
`was carried out in mice. Animals homozygous for the
`disruption had greatly deteriorated glucose tolerance and
`fasting hyperglycaemia, and even heterozygous animals
`were glucose intolerant (24). The signal transduction mecha
`nism (25) primarily involves activation of adenylate cyclase,
`but elevations of intracellular Ca" are also essential (25,
`26). The action of the hormone is best described as a
`potentiation of glucose Stimulated insulin release (25), but
`the mechanism that couples glucose and GLP-1 Stimulation
`is not known. It may involve a calcium-induced calcium
`release (26, 27). AS already mentioned, the insulinotropic
`action of GLP-1 is preserved in diabetic f-cells. The relation
`of the latter to its ability to convey "glucose competance' to
`isolated insulin-Secreting cells (26, 28), which respond
`poorly to glucose or GLP-1 alone, but fully to a combination
`of the two, is also not known. Equally importantly, however,
`the hormone also potently inhibits glucagon Secretion (29).
`The mechanism is not known, but seems to be paracrine, Via
`neighbouring insulin or Somatostatin cells (25). Also the
`glucagonostatic action is glucose-dependent, So that the
`inhibitory effect decreases as blood glucose decreases.
`Because of this dual effect, if the plasma GLP-1 concentra
`tions increase either by increased Secretion or by exogenous
`infusion the molar ratio of insulin to glucagon in the blood
`that reaches the liver via the portal circulation is greatly
`increased, whereby hepatic glucose production decreases
`(30). As a result blood glucose concentrations decrease.
`Because of the glucose dependency of the insulinotropic and
`glucagonostatic actions, the glucose lowering effect is Self
`limiting, and the hormone, therefore, does not cause
`hypoglycaemia regardless of dose (31). The effects are
`preserved in patients with diabetes mellitus (32), in whom
`infusions off slightly Supraphysiological doses of GLP-1
`may completely normalise blood glucose values in Spite of
`poor metabolic control and Secondary failure to Sulphony
`lurea (33). The importance of the glucagonostatic effect is
`illustrated by the finding that GLP-1 also lowers blood
`glucose in type-1 diabetic patients without residual B-cell
`Secretory capacity (34).
`In addition to its effects on the pancreatic islets, GLP-1
`has powerful actions on the gastrointestinal tract. Infused in
`physiological amounts GLP-1 potently inhibits pentagastrin
`induced as well as meal-induced gastric acid Secretion (35,
`36). It also inhibits gastric emptying rate and pancreatic
`enzyme secretion (36). Similar inhibitory effects on gastric
`and pancreatic Secretion and motility may be elicited in
`humans upon perfusion of the ileum with carbohydrate- or
`lipid-containing solutions (37, 38). Concomitantly, GLP-1
`Secretion is greatly Stimulated, and it has been speculated
`that GLP-1 may be at least partly responsible for this
`so-called “ileal-brake' effect (38). In fact, recent studies
`Suggest that, physiologically, the ileal-brake effects of
`GLP-1 may be more important than its effects on the
`pancreatic islets. Thus, in dose response Studies GLP-1
`influences gastric emptying rate at infusion rates at least as
`low as those required to influence islet secretion (39).
`GLP-1 seems to have an effect on food intake. Intraven
`tricular administration of GLP-1 profoundly inhibits food
`intake in rats (40, 42). This effect seems to be highly
`specific. Thus, N-terminally extended GLP-1 (PG 72-107)
`amide is inactive and appropriate doses of the GLP-1
`antagonist, exendin 9-39, abolish the effects of GLP-1 (41).
`
`15
`
`25
`
`35
`
`40
`
`45
`
`50
`
`4
`Acute, peripheral administration of GLP-1 does not inhibit
`food intake acutely in rats (41, 42). However, it remains
`possible that GLP-1 secreted from the intestinal L-cells may
`also act as a Satiety signal.
`Not only the insulinotropic effects but also the effects of
`GLP-1 on the gastrointestinal tract are preserved in diabetic
`patients (43), and may help curtailing meal-induced glucose
`excursions, but, more importantly, may also influence food
`intake. Administered intravenously, continuously for one
`week, GLP-1 at 4 ng/kg/min has been demonstrated to
`dramatically improve glycaemic control in NIDDM patients
`without significant side effects (44). The peptide is fully
`active after Subcutaneous administration (45), but is rapidly
`degraded mainly due to degradation by dipeptidyl peptidase
`IV-like enzymes (46, 47).
`The amino acid Sequence of GLP-1 is given i.a. by
`Schmidt et al. (Diabetologia 28 704–707 (1985). Human
`GLP-1 is a 37 amino acid residue peptide originating from
`preproglucagon which is Synthesised, i.a. in the L-cells in
`the distal ileum, in the pancreas and in the brain. Processing
`of preproglucagon to GLP-1 (7-36)amide, GLP-1 (7–37)
`and GLP-2 occurs mainly in the L-cells. Although the
`interesting pharmacological properties of GLP-1 (7-37) and
`analogues thereof have attracted much attention in recent
`years only little is known about the Structure of these
`molecules. The secondary structure of GLP-1 in micelles
`have been described by Thorton et al. (Biochemistry 33
`3532-3539 (1994)), but in normal solution, GLP-1 is con
`sidered a very flexible molecule. Surprisingly, we found that
`derivatisation of this relatively small and very flexible
`molecule resulted in compounds whose plasma profile were
`highly protracted and Still had retained activity.
`GLP-1 and analogues of GLP-1 and fragments thereof are
`useful i.a. in the treatment of Type 1 and Type 2 diabetes and
`obesity.
`WO 87/06941 discloses GLP-1 fragments, including
`GLP-1 (7-37), and functional derivatives thereof and to
`their use as an insulinotropic agent.
`WO 90/11296 discloses GLP-1 fragments, including
`GLP-1 (7-36), and functional derivatives thereof which
`have an insulinotropic activity which exceeds the insulino
`tropic activity of GLP-1 (1-36) or GLP-1 (1-37) and to their
`use as insulinotropic agents.
`The amino acid sequence of GLP-1 (7-36) and GLP-1
`(7–37) is (SEQ ID NO:1):
`
`9 10 11 12 13 14 15 16 17
`8
`7
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser
`
`(I)
`
`18 19 20 21 22 23 24 25 26 27 28
`Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe
`
`55
`
`29 30 31. 32 33 34 35 36
`Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-X
`wherein X is H for GLP-1 (7-36) and X is Gly for GLP-1
`(7–37).
`WO 91/11457 discloses analogues of the active GLP-1
`peptides 7-34, 7-35, 7-36, and 7-37 which can also be
`useful as GLP-1 moieties.
`EP 0708179-A2 (Eli Lilly & Co.) discloses GLP-1 ana
`logues and derivatives that include an N-terminal imidazole
`group and optionally an unbranched Co-Co acyl group in
`attached to the lysine residue in position 34.
`
`60
`
`65
`
`MPI EXHIBIT 1034 PAGE 4
`
`DR. REDDY’S LABORATORIES, INC.
`IPR2024-00009
`Ex. 1034, p. 4 of 137
`
`

`

`US 6,268,343 B1
`
`S
`EP 06996.86-A2 (Eli Lilly & Co.) discloses certain
`N-terminal truncated fragments of GLP-1 that are reported
`to be biologically active.
`Unfortunately, the high clearance limits the usefulness of
`these compounds. Thus there still is a need for improve
`ments in this field.
`Accordingly, it is an object of the present invention to
`provide derivatives of GLP-1 and analogues thereof which
`have a protracted profile of action relative to GLP-1 (7–37).
`It is a further object of the invention to provide derivatives
`of GLP-1 and analogues thereof which have a lower clear
`ance than GLP-1 (7–37).
`It is a further object of the invention to provide a phar
`maceutical composition with improved Solubility and Sta
`bility.
`
`5
`
`15
`
`6
`15. Buhl T, Thim L., Kofod H, Orskov C, Harling H, &
`Holst J.J. Naturally occurring products of proglucagon
`111-160 in the porcine and human Small intestine. J. Biol.
`Chem. 1988; 263:8621-8624.
`16. Orskov C, Buhl T, Rabenho. L, Kofod H, Holst JJ:
`Carboxypeptidase-B-like processing of the C-terminus of
`glucagon-like peptide-2 in pig and human Small intestine.
`FEBS letters, 1989; 247: 193-106.
`17. Holst J.J. Evidence that enteroglucagon (II) is identical
`with the C-terminal sequence (residues 33-69) of glicentin.
`Biochem J. 1980; 187:337-343.
`18. Bataille D, Tatemoto K, Gespach C, Jornvall H,
`Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive
`enteroglucagon/oxyntomodulin) from porcine jejuno-ileum.
`Characterisation of the peptide. FEBS Lett 1982;
`146:79-86.
`19. Orskov C, Wettergren A, Holst J.J. The metabolic rate
`and the biological effects of GLP-1 7-36amide and GLP-1
`7-37 in healthy volunteers are identical. Diabetes 1993;
`42:658-661.
`20. Elliott RM, Morgan LM, Tredger JA, Deacon S,
`Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide
`and glucose-dependent insulinotropic polypeptide Secretion
`in response to nutrient ingestion in man: acute post-prandial
`and 24-h secretion patterns. J Endocrinol 1993; 138:
`159-166.
`21. Kolligs F, Fehmann HC, Göke R, Göke B. Reduction
`of the incretin effect in rats by the glucagon-like peptide-1
`receptor antagonist exendin (9–39)amide. Diabetes 1995;
`44: 16-19.
`22. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei M.,
`Bloom SR. Glucagon-like peptide-1 is a physiological incre
`tin in rat. J. Clin. Invest. 1995; 95:417-421.
`23. Thorens B. Expression cloning of the pancreatic b cell
`receptor for the gluco-incretin hormone glucagon-like pep
`tide 1. Proc Natl Acad Sci 1992; 89:8641-4645.
`24. Scrocchi L, Auerbach AB, Joyner AL, Drucker DJ.
`Diabetes in mice with targeted disruption of the GLP-1
`receptor gene. Diabetes 1996; 45, 21A.
`25. Fehmann HC, Göke R, Göke G. Cell and molecular
`biology of the incretin hormones glucagon-like peptide-I
`(GLP-1) and glucose-dependent insulin releasing polypep
`tide (GIP). Endocrine Reviews, 1995; 16:390-410.
`26. Gromada J, Dissing S, Bokvist K, Renström E,
`Frokjaer-Jensen J, Wulff BS, Rorsman P. Glucagon-like
`pepide I increases cytoplasmic calcium in insulin-Secreting
`bTC3-cells by enhancement of intracellular calcium mobili
`sation. Diabetes 1995; 44:767-774.
`27. Holz GG, Leech CA, Habener JF, Activation of a
`cAMP-regulated Ca"-signaling pathway in pancreatic
`B-cells by the insulinotropic hormone glucagon-like
`peptide-1. J. Biol Chem, 1996; 270: 17749–17759.
`28. Holz GG, Kühltreiber WM, Habener JF, Pancreatic
`beta-cells are rendered glucose competent by the insulino
`tropic hormone glucagon-like peptide-1 (7–37). Nature
`1993; 361:362-365.
`29. Orskov C, Holst JJ, Nielsen OV: Effect of truncated
`glucagon-like peptide 1 (Proglucagon 78-107 amide) on
`endocrine Secretion from pig pancreas, antrum and Stomach.
`Endocrinology 1988; 123:2009–2013.
`30. Hvidberg A, Toft Nielsen M, Hilsted J, Orskov C,
`Holst J.J. Effect of glucagon-like peptide-1 (proglucagon
`78-107amide) on hepatic glucose production in healthy
`man. Metabolism 1994; 43:104-108.
`
`25
`
`35
`
`References
`1. Pederson RA. Gastric Inhibitory Polypeptide. In Walsh
`JH, Dockray GJ (eds) Gut peptides: Biochemistry and
`Physiology. Raven Press, New York 1994, pp. 217259.
`2. Krarup T. Immunoreactive gastric inhibitory polypep
`tide. Endocr Rev 1988;9: 122-134.
`3. Orskov C. Glucagon-like peptide-1, a new hormone of
`the enteroinsular axis. Diabetologia 1992; 35:701-711.
`4. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian
`RC. EXon duplication and divergence in the human prepro
`glucagon gene. Nature 1983; 304; 368-371.
`5. Holst J.J. Glucagon-like peptide-1 (GLP-1)-a newly
`discovered GI hormone. Gastroenterolgoy 1994; 107:
`1848-1855.
`6. Holst J.J. Gut glucagon, enteroglucagon, gut GLI,
`glicentin-current Status. Gastroenterology 1983;
`84:1602-1613.
`7. Holst JJ, Orskov C. Glucagon and other proglucagon
`derived peptides. In Walsh JH, Dockray GJ, eds. Gut pep
`tides: Biochemistry and Physiology, Raven Press, New
`York, pp. 305-340, 1993.
`40
`8. Orskov C, Holst J.J. Knuhtsen S, Baldissera FGA,
`Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and
`GLP-2, predicted products of the glucagon gene, are
`Secreted Separately from the pig Small intestine, but not
`pancreas. Endocrinology 1986; 119:1467–1475.
`9. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann
`B, Orskov C. Proglucagon processing in porcine and human
`pancreas. J Biol Chem, 1994; 269; 18827–1883.
`10. Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship
`of glicentin to proglucagon and glucagon in the porcine
`pancreas. Nature 1981; 289: 514-516.
`11. Thim L, Moody AJ, Purification and chemical char
`acterisation of a glicentin-related pancreatic peptide
`(proglucagon fragment) from porcine pancreas. Biochim
`Biophys Acta 1982; 703:134-141.
`12. Thim L. Moody AJ. The primary structure of glicentin
`(proglucagon). Regul Pept 1981; 2:139-151.
`13. Orskov C, Bersani M, Johnsen AH, Hojrup P. Holst J.J.
`Complete Sequences of glucagon-like peptide-1 (GLP-1)
`from human and pig Small intestine. J. Biol. Chem. 1989;
`264:12826-12829.
`14. Orskov C, Rabenho. L, Kofod H, Wettergren A, Holst
`J.J. Production and Secretion of amidated and glycine
`extended glucagon-like peptide-1 (GLP-1) in man. Diabetes
`1991; 43: 535-539.
`
`45
`
`50
`
`55
`
`60
`
`65
`
`MPI EXHIBIT 1034 PAGE 5
`
`DR. REDDY’S LABORATORIES, INC.
`IPR2024-00009
`Ex. 1034, p. 5 of 137
`
`

`

`7
`31. Qualmann C, Nauck M, Holst JJ, Orskov C.
`Creutzfeldt W. Insulinotropic actions of intravenous
`glucagon-like peptide-17-36 amide in the fasting State in
`healthy Subjects. Acta Diabetologica, 1995; 32:13-16.
`32. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert
`R, Creutzfeldt W. Preserved incretin activity of GLP-1
`(7-36amide) but not of synthetic human GIP in patients with
`type 2-diabetes mellitus. J Clin Invest 1993; 91:301-307.
`33. Nauck MA, Kleine N, Orskov C. Holst JJ, Willms B,
`Creutzfeldt W. Normalisation of fasting hyperglycaemia by
`exogenous GLP-1(7-36amide) in type 2-diabetic patients.
`Diabetologia 1993; 36:741-744.
`34. Creutzfeldt W. Kleine N, Willms B, Orskov C, Holst
`JJ, Nauck MA. Glucagonostatic actions and reduction of
`fasting hyperglycaemia by exogenous glucagon-liem,
`peptide-1 (7-36amide) in type 1 diabetic patients. Diabetic
`Care 1996; 19: 580-586.
`35. Schjoldager BTG, Mortensen PE, Christiansen J,
`Orskov C, Holst J.J. GLP-1 (glucagon-like peptide-1) and
`truncated GLP-1, fragments of human proglucagon, inhibit
`gastric acid secretion in man. Dig. Dis. Sci. 1989;
`35:703-708.
`36. Wettergren A, Schjoldager B, Mortensen PE, Myhre J,
`Christiansen J, Holst J.J. Truncated GLP-1 (proglucagon
`72-107amide) inhibits gastric and pancreatic functions in
`man. Dig Dis Sci 1993; 38:665–673.
`37. Layer P, Holst JJ, Grandt D, Goebell H: Ileal release
`of glucagon-like peptide-1 (GLP-1): association with inhi
`bition of gastric acid in humans. Dig Dis Sci 1995; 40:
`1074-1082.
`38. Layer P, Holst J.J. GLP-1: A humoral mediator of the
`ileal brake in humans? Digestion 1993; 54:385–386.
`39. Nauck M, Ettler R, Niedereichholz U, Orskov C,
`Holst JJ, Schmiegel W. Inhibition of gastric emptying by
`GLP-1 (7-36 amide) or (7–37); effects on postprandial gly
`caemia and insulin secretion. Abstract. Gut 1995; 37 (suppl.
`2); A124.
`40. Schick RR, vorm Walde T, Zimmermann JP, Schus
`dZiarra V, Classen M Glucagon-like peptide 1-a novel
`brain peptide involved in feeding regulation. in DitSchuneit
`H, Gries FA, Hauner H, Schusdziarra V. Wechsler JG (eds.)
`Obesity in Europe. John Libbey & Company ltd, 1994; pp.
`363-367.
`41. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen
`A, Jessop DS, Moller M, Sheikh S. Brian GLP-1(7–36)
`amide receptors play a major role in regulation of food and
`water intake. Am. J. Physiol., 1996, in press.
`42. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards
`CMB, Meeran K, et al. A role for glucagon-like peptide-1 in
`the regulation of feeding. Nature 1996; 379; 69–72.
`43. Willms B, Werner J, Creutzfeldt W, Orskov C, Holst
`JJ, Nauck M. Inhibition of gastric emptying by glucagon
`like peptide-1 (7-36amide) in patients with type-2-diabetes
`mellitus. Diabetologia 1994; 37, suppl. 1: A118.
`44. Larsen J, Jallad N, Damsbo P. One-week continuous
`infusion of GLP-1 (7-37) improves glycaemic control in
`NIDDM. Diabetes 1996; 45, suppl. 2: 233A.
`45. Ritzel R, Orskov C, Holst JJ, Nauck MA.
`Pharmacokinetic, insulinotropic, and glucagonstatic proper
`ties of GLP-17-36 amide after subcutaneous injection in
`healthy Volunteers. Dose-response relationships. Diabetolo
`gia 1995; 38: 720–725.
`
`15
`
`25
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`US 6,268,343 B1
`
`8
`46. Deacon CF, Johnson AH, Holst J.J. Degradation of
`glucagon-like peptide-1 by human plasma in vitro yields an
`N-terminally truncated peptide that is a major endogenous
`metabolite in vivo. J. Clin Endocrinol Metab 1995; 80:
`952-957.
`47. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L,
`Willms B, Holst JJ, 1995. Both Subcutaneous and intrave
`nously administered glucagon-like peptide-1 are rapidly
`degraded from the amino terminus in type II diabetic
`patients and in healthy subjects. Diabetes 44: 1126–1131.
`SUMMARY OF THE INVENTION
`The present invention relates to derivatives of GLP-1
`(1-45) and analogs and/or fragments thereof. The GLP-1
`derivatives of the present invention have interesting phar
`macological properties, in particular they have a more
`protracted profile of action than the parent peptides. The
`GLP-1 derivatives of the present invention also have insuli
`notropic activity, ability to decrease glucagon, ability to
`SuppreSS gastric motility, ability to restore glucose compe
`tency to beta-cells, and/or ability to SuppreSS appetite/reduce
`weight.
`BRIEF DESCRIPTION OF THE FIGURES
`FIG. 1 shows the results of Circular Dichroism (CD) at
`222 nm as a function of peptide concentration for native
`GLP-1 (7-37) and various GLP-1 derivatives of the present
`invention.
`
`DETAILED DESCRIPTION OF THE
`INVENTION
`A simple System is used to describe fragments and ana
`logues of GLP-1. For example, Gly-GLP-1(7–37) desig
`nates a peptide which relates to GLP-1 by the deletion of the
`amino acid residues at positions. 1 to 6 and Substituting the
`naturally occurring amino acid residue in position 8 (Ala) by
`Gly. Similarly, Lys'(N-tetradecanoyl)-GLP-1(7–37) des
`ignates GLP-1 (7-37) wherein the e-amino group of the Lys
`residue in position 34 has been tetradecanoylated. Where
`reference in this text is made to C-terminally extended
`GLP-1 analogues, the amino acid residue in position 38 is
`Arg unless otherwise indicated, the amino acid residue in
`position 39 is also Arg unless otherwise indicated and the
`optional amino acid residue in position 40 is Asp unless
`otherwise indicated. Also, if a C-terminally extended ana
`logue extends to position 41, 42, 43, 44 or 45, the amino acid
`Sequence of this extension is as in the corresponding
`Sequence in human preproglucagon unless otherwise indi
`cated.
`GLP-1. Analogs
`The term “an analogue' is defined herein as a peptide
`wherein one or more amino acid residues of the parent
`peptide have been Substituted by another amino acid residue.
`In a preferred embodiment, the total number of different
`amino acids between the GLP-1 derivative and the corre
`sponding native form of GLP-1 is up to fifteen, preferably up
`to ten amino acid residues, and most preferably up to Six
`amino acid residues.
`The total number of different amino acids between the
`derivative of the GLP-1 analog and the corresponding native
`form of GLP-1 preferably does not exceed six. Preferably,
`the number of different amino acids is five. More preferably,
`the number of different amino acids is four. Even more
`preferably, the number of different amino acids is three.
`
`MPI EXHIBIT 1034 PAGE 6
`
`DR. REDDY’S LABORATORIES, INC.
`IPR2024-00009
`Ex. 1034, p. 6 of 137
`
`

`

`US 6,268,343 B1
`
`9
`Even more preferably, the number of different amino acids
`is two. Most preferably, the number of different amino acids
`is one. In order to determine the number of different amino
`acids, one should compare the amino acid Sequence of the
`GLP-1 derivative of the present invention with the corre
`sponding native GLP-1. For example, there are two different
`amino acids between the derivative GlyArg-Lys-(N-(7-
`deoxycholoyl)-GLP-1 (7-40) and the corresponding native
`GLP-1 (i.e., GLP-1 (7-40)). The differences are located at
`positions 8 and 26. Similarly, there is only one different
`amino acid between the derivative Lys (N-(7-
`deoxycholoyl))Arg-GLP-1(7–40) and the corresponding
`native GLP-1. The difference is located at position 34.
`In a preferred embodiment, the present invention relates
`to a GLP-1 derivative wherein the parent peptide is GLP-1
`(1-45) or an analogue thereof. In a further preferred
`embodiment, the parent peptide is GLP-1(1-35), GLP-1
`(1–36), GLP-1(1-36)amide, GLP-1(1-37), GLP-1(1-38),
`GLP-1(1-39), GLP-1(1-40), GLP-1(1-41) or an analogue
`thereof.
`In a preferred embodiment, the present invention relates
`to derivatives of GLP-1 analogues of formula I (SEQ ID
`NO:2):
`
`9 10 11 12 13 14 15 16 17
`8
`7
`Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa
`
`(I)
`
`18, 19 20 21 22 23 24 25 26 27 28
`Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Phe
`
`32 33 34 35 36 37 38
`29 30 31.
`Ile-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa
`
`42 4 3 44 45
`39 40 41.
`Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa
`
`wherein
`Xaa at position 7 is His, a modified amino acid or is
`deleted,
`Xaa at position 8 is Ala, Gly, Ser, Thr, Leu, Ile, Val, Glu,
`Asp, or LyS, or is deleted,
`Xaa at position 9 is Glu, Asp, or LyS, or is deleted,
`Xaa at position 10 is Gly or is deleted,
`Xaa at po

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket